An­oth­er 14 gener­ics threat­en Eli Lil­ly's block­buster chemother­a­py Al­im­ta

Eli Lil­ly was able to fend off gener­ic com­pe­ti­tion to its chemother­a­py drug Al­im­ta for quite some time, de­fend­ing its patents in a se­ries of le­gal bat­tles. But as of last week, the drug has 14 new copy­cats to con­tend with.

The FDA last Wednes­day ap­proved 14 ab­bre­vi­at­ed new drug ap­pli­ca­tions (AN­DAs) for Al­im­ta gener­ics, in­clud­ing ones from Pfiz­er’s Hos­pi­ra and Dr. Red­dy’s, which had pre­vi­ous­ly en­gaged in patent bat­tles with Eli Lil­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER